Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IDEXX Laboratories, Inc. (IDXX) vs Unity Software Inc (U) Price & Performance

IDEXX Laboratories, Inc.Trade
Unity Software IncTrade

Price performance (Past 24H)

Key statistics

IDEXX Laboratories, Inc. vs Unity Software Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Unity Software Inc trades at $46.88 (market cap $20.20B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2× Unity Software Inc's market cap, and Unity Software Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Unity Software Inc for 50 Days on average.

IDXXU
Market Cap
$40.43B$20.20B
Volume
692,16415,432,191
Sector
HealthTechnology
52-Week High
$766.68$49.47
52-Week Low
$504.70$17.13
Typical Hold Time
46 Days50 Days
Enterprise Value
$41.32B$20.08B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.

Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.

Unity Software Inc

Unity Software (U) trades at $45.89, up 0.99% today, with strong analyst support (83% buy ratings) and a $46.54 consensus price target. Recent momentum is fueled by Meta VR partnership news and positive technical signals, though the stock faces fundamental challenges with negative profitability metrics and consecutive earnings misses. Cash flow trends show improvement with 2025 operating cash flow reaching $423 million.

The stock presents a growth opportunity with accelerating strategic revenue and AI platform transformation, but carries significant risk from persistent losses and high valuation multiples. Investors must weigh strong institutional support against ongoing profitability challenges and competitive pressures in the gaming engine market.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IDXX

No sentiment data available yet.

U
0% Buy100% Sell
Avg holding period · 50 Days

Top news

Latest headlines on both assets

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX →

About Unity Software Inc

Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.

Read more on U →